Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 606.10 INR
Change Today +0.15 / 0.02%
Volume 11.0K
HCBA On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:11 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

novartis india ltd (HCBA) Snapshot

Open
614.85
Previous Close
605.95
Day High
614.85
Day Low
601.10
52 Week High
09/9/14 - 760.00
52 Week Low
05/22/14 - 472.00
Market Cap
19.4B
Average Volume 10 Days
18.1K
EPS TTM
30.83
Shares Outstanding
32.0M
EX-Date
07/16/14
P/E TM
19.7x
Dividend
10.00
Dividend Yield
1.65%
Current Stock Chart for NOVARTIS INDIA LTD (HCBA)

Related News

No related news articles were found.

novartis india ltd (HCBA) Related Businessweek News

No Related Businessweek News Found

novartis india ltd (HCBA) Details

Novartis India Limited manufactures and sells healthcare products in India and internationally. It operates through four segments: Pharmaceuticals, Generics, Over-The-Counter, and Animal Health. The Pharmaceuticals segment offers a portfolio of prescription medicines in various therapeutic areas, including central nervous system, pain and inflammation, and transplantation/immunology through healthcare professionals primarily under the Voveran, Trioptal, Exelon, Tegrital, and Sandimmun Neoral brand names. This segment offers its products in various forms, such as tablets, capsules, liquid orals, injectables, creams and ointments, patches, and vials. The Generics segment offers retail generics products in various therapeutic areas, such as anti-TB, anti-DUB (gynecology), anti-histamines, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. This segment offers its products in tablet and liquid-oral forms. The Over-The-Counter segment offers vitamins, minerals, and nutritional supplements, as well as products for the treatment of cough, cold, and allergy primarily under the Otrivin, Otrinoz, and T-minic brand names. It offers its products in various forms, which include powders-vitamin and nutritional supplements, tablets, capsules, and liquid-orals. The Animal Health segment offers drug formulations and feed supplements in cattle and poultry markets. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.

1,294 Employees
Last Reported Date: 06/30/14
Founded in 1947

novartis india ltd (HCBA) Top Compensated Officers

Vice Chairman, Managing Director and Member o...
Total Annual Compensation: 16.8M
Compensation as of Fiscal Year 2014.

novartis india ltd (HCBA) Key Developments

Novartis India Limited expected to report Fiscal Year 2015 results on May 22, 2015. This event was calculated by Capital IQ (Created on February 9, 2015).

Novartis India Limited expected to report Fiscal Year 2015 results on May 22, 2015. This event was calculated by Capital IQ (Created on February 9, 2015).

Novartis India Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Novartis India Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported total income from operations (net) of INR 2,222 million compared to INR 2,235.3 million a year ago. Loss from operations before other income and finance costs was INR 189.4 million compared to INR 15.5 million a year ago. Profit from ordinary activities before tax was INR 44.4 million compared to INR 215.6 million a year ago. Net loss for the period was INR 11.8 million or INR 1.11 per basic and diluted share compared to net profit for the period of INR 152.3 million or INR 4.77 per basic and diluted share a year ago. For the nine months, the company reported total income from operations (net) of INR 6,657.4 million compared to INR 6,605.5 million a year ago. Loss from operations before other income and finance costs was INR 240.1 million compared to INR 114 million a year ago. Profit from ordinary activities before tax was INR 466.5 million compared to INR 576.4 million a year ago. Net profit for the period was INR 271.7 million or INR 9.98 per basic and diluted share compared to INR 746.5 million or INR 23.36 per basic and diluted share a year ago.

Novartis India Limited, Board Meeting, Feb 04, 2015

Novartis India Limited, Board Meeting, Feb 04, 2015. Agenda: To consider unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCBA:IN 606.10 INR +0.15

HCBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HCBA.
View Industry Companies
 

Industry Analysis

HCBA

Industry Average

Valuation HCBA Industry Range
Price/Earnings 34.4x
Price/Sales 2.2x
Price/Book 1.9x
Price/Cash Flow 35.1x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS INDIA LTD, please visit www.novartis.in/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.